Reduce costs with our complimentary sample for evaluation in your lab.
Inotiv delivers a broad array of nonclinical and analytical services from discovery through clinical development.
Inotiv provides the broadest range of research models and related services to pharmaceutical and biotech companies, government, academia, and other life science organizations.
March 19-23, 2023 Nashville, TN Booth #709 Toxicologists and scientists will attend the annual ToxExpo virtually to communicate industry-leading ideas and best practices. With live...
April 14-19, 2023 Orlando, FL Booth# 3354 The AACR Annual Meeting program covers the latest discoveries across the spectrum ...
April 23-26, 2023 Philadelphia, PA Booth #914 Join the Inotiv team of experts at the AAPS National Biotechnology Conference (NBC) held on Apr...
Read More<...
WEST LAFAYETTE, IN, February 6, 2023 — Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), is pleased to announce Jeff Krupp
Pinworms are an insidious and common threat to research utilizing laboratory mice and rats. This pest can adversely affect the reproducibility and reliability of research findings. Moreover, the parasitic load and adverse effects caused by pinworms can be even more pronounced in immunodeficient animals.
Looking to enhance the 3Rs and increase catheter patency at the same time? Cannulock™ Buttons can help. This innovative closed system improves animal and technician welfare while increasing catheter patency.
Three recent studies made it clear: the R2G2® mouse is well suited for preclinical cancer studies that generate PDX, CDX and allograft models. The R2G2® mouse exhibited reduced radiosensitivity compared to NSGTM mice and tolerated estrogen supplementation and three standard-of-care chemotherapy drugs reasonably well. Moreover, as compared to other traditionally used immunodeficient strains, the R2G2® mouse had higher take rates and more favorable tumor growth.
Copyright © Inotiv. All Rights Reserved.